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A B S T R A C T   
Importance: Exposure to phthalates may affect fetal growth, but previous studies are inconsistent and have not 
explored the trimester-specific effects of phthalates on repeated measures of fetal growth. 
Objective: To assess the associations of maternal phthalate metabolites urine concentrations with fetal growth 
measures and birth outcomes and identify potential windows of vulnerability to exposure. 
Design: Population-based prospective cohort study, the Generation R Study (2002–2006). Data analysis was 
performed from November 2019 to June 2020. 
Setting: Rotterdam, the Netherlands. 
Participants: 1379 pregnant women. 
Exposures: Maternal phthalate metabolites urine concentrations in first, second and third trimester. 
Main outcomes and measures: Fetal head circumference, length and weight measured in the second and third 
trimester by ultrasound and at birth and preterm birth and small size for gestational age at birth. 
Results: Higher pregnancy-averaged phthalic acid, low molecular weight phthalate (LMWP), high molecular 
weight phthalate (HMWP) and di-2-ethylhexylphthalate (DEHP) concentrations tended to be associated with 
lower fetal weight SDS across gestation. The associations of phthalic acid and LMWP with fetal weight became 
stronger as pregnancy progressed (differences − 0.08 (95% CI − 0.14 to − 0.02) SDS and − 0.09 (95% CI − 0.16 to 
− 0.02) SDS at 40 weeks per interquartile range increase in phthalic acid and LMWP, respectively). Higher 
concentrations of specific LMWP, HMWP and DEHP metabolites were also associated with smaller head 
circumference and lower length SDS at birth and an increased risk of preterm birth and small size for gestational 
age at birth (p-values < 0.05). We observed differences by timing of exposure in these associations. 
Conclusions and relevance: Higher maternal phthalate metabolites urine concentrations seem to be related with 
fetal growth restriction and preterm birth. Phthalates may have trimester specific effects on fetal growth and 
birth outcomes. Further studies are needed to explore the underlying mechanisms and long-term consequences.   
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1. Introduction 
Phthalates are endocrine disrupting chemicals and are widespread as 
plasticizers in polyvinyl chloride plastics, personal care products and 
some medical devices (Hauser and Calafat, 2005). We have previously 
reported, using data from the same cohort as the current study, associ-
ations of maternal phthalates during pregnancy with several maternal 
and childhood adverse health outcomes (Sol et al., 2020; Philips et al., 
2018b, 2019, 2020a, 2020b; van Zwol-Janssens et al., 2020; van den 
Dries et al., 2020). Phthalates are able to cross the placenta and may also 
adversely affect placental development and function, subsequently 
leading to suboptimal fetal growth and adverse birth outcomes (Mose 
et al., 2007; Yang et al., 2019). 
Previous studies on the associations of maternal phthalate metabo-
lites concentrations during pregnancy with fetal weight, length and head 
circumference measurements during pregnancy or at birth showed 
inconsistent results (Kamai et al., 2019; Kalloo et al., 2020; Bloom et al., 
2019; Noor et al., 2019; Botton et al., 2016; Ferguson et al., 2016; Casas 
et al., 2016) Fetal exposure to phthalates seems to be associated with an 
increased risk of preterm birth (Kalloo et al., 2020; Bloom et al., 2019; 
Chin et al., 2019; Ferguson et al., 2014; Gao et al., 2019; Boss et al., 
2018; Zhang et al., 2020; Ferguson et al., 2019). To our knowledge, the 
associations of phthalates exposure with fetal growth assessed longitu-
dinally during pregnancy have been poorly investigated. In a prospec-
tive cohort study among 520 mother-son pairs from France, maternal 
high-molecular-weight phthalate (HMWP) urine concentrations tended 
to be negatively associated with estimated fetal weight throughout 
pregnancy (Botton et al., 2016). A case-control study among 130 pre-
term children and 352 random term singleton controls showed that 
cumulative exposure to mono-2-ethyl-5-carboxypentyl phthalate, mono- 
benzyl phthalate and sum of di-2-ethylhexyl phthalate (DEHP) metab-
olites was associated with lower growth of head circumference, femur 
length and estimated weight between 26 and 35 weeks (Ferguson et al., 
2016). In a prospective cohort study among 390 mother–child pairs, 
fetal mono-benzyl phthalate exposure was associated with increased 
femur length growth from 20 to 34 weeks, while fetal mono-n-butyl 
phthalate exposure was associated with lower head circumference 
growth from 12 to 20 weeks (Casas et al., 2016). Analyses on repeated 
measures of fetal growth allow detecting critical periods and growth 
variation during gestation that might not be fully captured by a single 
measurement at a specific time point during pregnancy or at delivery. 
The trimester-specific effects of phthalates on repeated measures of fetal 
growth and birth outcomes also remain largely unknown (Ferguson 
et al., 2016). 
We examined, among 1379 women participating in a population- 
based cohort study, the associations of maternal phthalate metabolites 
urine concentrations at three time points in pregnancy, with fetal head 
circumference, length and weight measured at two time points during 
pregnancy and at birth and with the risks of preterm birth and being 
born small size for gestational age at birth. 
2. Material and methods 
2.1. Study design 
This study was embedded in the Generation R Study, a population- 
based prospective cohort study from early fetal life onwards in Rotter-
dam, the Netherlands (Kooijman et al., 2016). The study was approved 
by the Medical Ethics Committee of Erasmus MC, University Medical 
Center in Rotterdam. Written informed consent was obtained from all 
participants. The current study is part of a research line within the 
Generation R Study that aims to assess the associations of maternal 
phthalates and bisphenols during pregnancy with several maternal, fetal 
and childhood outcomes (Sol et al., 2020; Philips et al., 2018b, 2019, 
2020a, 2020b; van Zwol-Janssens et al., 2020; van den Dries et al., 
2020) Phthalate urine concentrations were measured among 1405 
mothers with three urine samples available in pregnancy, whose 
singleton children participated in postnatal studies. Women in this 
subgroup were similar to the Generation R cohort in terms of socio- 
demographic and lifestyle characteristics. (Philips et al., 2018a) We 
excluded mothers without information on phthalate urine concentra-
tions in at least one trimester. The population for analysis comprises 
1379 pregnant women (specific sample per outcome in eFigure S1). 
2.2. Maternal phthalate urine concentrations 
Phthalate metabolites concentrations were measured in spot urine 
samples obtained at early pregnancy (median 12.9 weeks of gestation, 
25th-75th percentiles 12.1–14.5), mid-pregnancy (median 20.4 weeks 
of gestation, 25th-75th percentiles 20.4–20.9) and late pregnancy (me-
dian 30.2 weeks of gestation, 25th-75th percentiles 29.9–30.8). These 
periods were considered first, second and third trimester. Urine samples 
were collected between February 2004 and July 2005. Details on 
collection, transportation, and analysis methodology have been 
described previously (Philips et al., 2018a). Regarding assay related 
variabilities, repeated analysis of same samples overtime yielded a co-
efficient of variation <15% for all phthalates measured. We grouped 
phthalate metabolites according to their molecular weight categories 
and parent compounds. Individual phthalate metabolites were included 
in groups and assessed individually if <80% of the sample concentra-
tions were below the limit of detection (LOD). We calculated the 
weighted molar sums for groups representing low-molecular-weight 
phthalates (LMWP), HMWP, and for two subgroups within HMWP, 
namely DEHP and di-n-octylphthalate (DNOP) metabolites. Phthalic 
acid was analyzed separately as proxy for total phthalate exposure. 
Phthalate concentrations below LOD were substituted by LOD/√2 
(Hornung, 1990). To account for urine dilution, urine concentrations 
were converted to µg/g creatinine (separate metabolites) or µmol/g 
creatinine (metabolite groups). eTable S1 shows the descriptive statis-
tics of the individual and grouped phthalate metabolites. Intraclass 
correlation coefficients between natural log-transformed phthalates 
across pregnancy were assessed using a single measurement, absolute 
agreement and two-way mixed effects model and varied between 0.10 
and 0.40. This suggests high within-individual variation, which might 
reflect the short biological half-lives of these compounds (Casas et al., 
2018). Assuming that exposures are relatively consistent over preg-
nancy, we calculated average concentrations based on first, second and 
third trimester phthalate concentrations and used this as a measure of 
usual exposure during pregnancy. 
2.3. Fetal growth measures and birth outcomes 
Fetal examinations were performed in each trimester using stan-
dardized ultrasound procedures (Royal College of Obstetricians and 
Gynaecologists, 2000; Verburg et al., 2008). Gestational age at the time 
of growth measurements in second and third trimester was based on the 
first trimester ultrasound (Verburg et al., 2008). In second and third 
trimester, we measured fetal head circumference and femur length to 
the nearest millimeter (Royal College of Obstetricians and Gynaecolo-
gists, 2000). Estimated fetal weight was calculated using the formula of 
Hadlock et al. (1985) Gestational-age-adjusted standard deviation 
scores (SDS) were calculated using reference growth curves derived in 
the same cohort as the current study (Verburg et al., 2008). At birth, 
information on gestational age, head circumference, length and weight 
was obtained from medical records. Head circumference and length 
were not routinely measured, and thus fewer measurements were 
available (eFig. S1). We created sex- and gestational age-adjusted SDS 
for weight, length and head circumference at birth based on North Eu-
ropean reference charts (Niklasson et al., 1991). The median (95% 
range) gestational ages for second and third trimester ultrasounds and at 
birth were 20.4 (18.9, 22.7), 30.4 (28.7, 32.6), and 40.3 (36.7, 42.3) 
weeks, respectively. Preterm birth was defined as <37 weeks of 
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gestation. Small size for gestational age at birth was defined in the whole 
Generation R study population as sex- and gestational age-adjusted birth 
weight <10th percentile (− 1.41 SD). Appropriate size for gestational 
age at birth was used as the reference group. 
2.4. Covariates 
Information on maternal age, parity, educational level, ethnicity, 
pre-pregnancy weight, folic acid supplement use, smoking habits and 
alcohol consumption was obtained from questionnaires during preg-
nancy. Maternal height was measured at enrollment and pre-pregnancy 
body mass index (BMI, kg/m2) was calculated. Maternal daily caloric 
intake was estimated from a validated food frequency questionnaire 
covering the average intake in first trimester (Klipstein-Grobusch et al., 
1998; Tielemans et al., 2016). 
2.5. Statistical analysis 
We natural log-transformed the creatinine-adjusted phthalate me-
tabolites urine concentrations to reduce variability and account for right 
skewedness of the distribution and standardized by the interquartile 
range (IQR) to ease interpretation of effect sizes. We performed linear 
mixed effects models to assess the associations of the pregnancy- 
averaged phthalate metabolites urine concentrations with head 
circumference, length or weight SDS repeatedly measured in the second 
and third trimester and at birth. Non-linearity of the associations was 
ruled out using generalized additive models. All models included a 
random intercept and slope. We additionally included an interaction 
term between pregnancy-averaged phthalate metabolites urine con-
centrations and gestational age to allow the exposure-outcome associ-
ation to change across pregnancy. When associations differ by timing of 
outcome measurement, the main effects obtained represent the effect 
estimates at 0 weeks of gestation and thus lack interpretability. There-
fore, we centered the gestational age at growth measurement at 20, 30 
and 40 weeks to obtain the effect estimates at these specific time points. 
We performed linear regression models to assess the associations of 
phthalate metabolites concentrations in first, second and third trimester 
with outcome measurements in second and third trimester and at birth. 
For these analyses, we examined only outcomes at the same or subse-
quent time points as the exposure. We performed binary logistic 
regression models to assess the associations of phthalate metabolites 
urine concentrations with risks of preterm birth and small size for 
gestational age at birth. Due to the low number of preterm births and 
potential lack of power, we performed a sensitivity analysis with 
continuous gestational age at birth as outcome. We examined the in-
dependent associations of maternal first, second and third trimester 
phthalate metabolites concentrations by simultaneously including in 
one model the exposures at all three trimesters. We defined as potential 
confounders any lifestyle, nutritional or sociodemographic character-
istic that has been related to exposure to phthalates in pregnancy and 
fetal growth and birth outcomes in previous studies. We have previously 
observed, using data from the current cohort study, that adverse lifestyle 
factors including obesity and the lack of folic acid supplement use are 
associated with higher phthalate concentrations in pregnant women. 
(Philips et al., 2018a) We depicted the potential relationships between 
all exposures, covariates and outcomes in a directed acyclic graph 
(simplified version presented in eFig. S2) and checked if all fulfilled the 
graphical criteria for confounding, i.e., if all potential covariates block 
an otherwise open backdoor path (Santos et al., 2019). The covariates 
identified were included in the models when they changed the effect 
estimates >10% for at least one outcome. Since the mechanism of action 
of phthalates on placenta formation may be sex-specific, we tested for 
statistical interaction between phthalate metabolites urine concentra-
tions with fetal sex in these associations (Sood et al., 2017). Folic acid is 
known to influence the metabolism of phthalates, and thus we also 
tested for statistical interaction with folic acid supplement use (Crider 
et al., 2012). We did not find statistically significant interactions (p- 
values > 0.10) and no stratified analyses were performed. To correct for 
multiple hypothesis testing, each p-value was compared with a 
threshold defined as 0.05 divided by the effective number of indepen-
dent tests estimated based on the correlation between the exposures (p- 
value threshold of 0.007) (Li et al., 2012). Missing data in covariates 
(ranging from 0 to 25%) were multiple imputed using the Markov Chain 
Monte Carlo method. Ten imputed datasets were created and analyzed 
together. Statistical analyses were performed using the Statistical 
Package of Social Sciences version 25.0 for Windows (SPSS Inc., Chi-
cago, IL, USA) and R software (version 3.6.1). We used the software 
package nlme for the linear mixed effects models. 
3. Results 
3.1. Subject characteristics 
Table 1 shows the characteristics of study participants. The mean 
maternal age was 30.5 years, 7.4% were lower educated, 61.9% of all 
women were European and the median pre-pregnancy BMI was 22.7 kg/ 
m2. In total, 2.5% of all women had a preterm delivery. 
3.2. Maternal phthalate metabolites concentrations and fetal growth 
measures 
We did not observe associations between all maternal pregnancy- 
averaged phthalate metabolites urine concentrations and fetal head 
Table 1 
Characteristics of study participants (n = 1,379).   
Total group (n =
1379) 
Maternal characteristics  
Age, mean (SD), years 30.5 (4.8) 
Parity, No. nulliparous (%) 839 (61.2) 
Educational level, No. low (%) 102 (7.4) 
Ethnicity, No. European (%) 846 (61.9) 
Pre-pregnancy body mass index, median (95% range), kg/ 
m2 
22.7 (18.5, 34.9) 
Smoking, No. nonsmoking (%) 939 (75.5) 
First trimester, No. nonsmoking (%) 952 (78.4) 
Second trimester, No. nonsmoking (%) 1055 (88.7) 
Third trimester, No. nonsmoking (%) 1050 (89.3) 
Alcohol consumption, No. no alcohol use (%) 527 (42.6) 
First trimester, No. no alcohol use (%) 616 (50.5) 
Second trimester, No. no alcohol use (%) 777 (65.6) 
Third trimester, No. no alcohol use (%) 747 (63.5) 
Folic acid supplement use, No. yes (%) 887 (80.6) 
Daily caloric intake, mean (SD), kcal 2078.1 (511.2) 
Fetal growth characteristics  
Second trimester  
Gestational age, median (95% range), weeks 20.4 (18.9, 22.7) 
Head circumference, mean (SD), mm 178.0 (12.0) 
Femur length, mean (SD), mm 33.2 (2.9) 
Estimated fetal weight, mean (SD), g 369.2 (72.7) 
Third trimester  
Gestational age, median (95% range), weeks 30.4 (28.7, 32.6) 
Head circumference, mean (SD), mm 285.9 (11.5) 
Femur length, mean (SD), mm 57.5 (2.8) 
Estimated fetal weight, mean (SD), g 1620.5 (236.5) 
Birth characteristics  
Males, No. (%) 696 (50.5) 
Gestational age, median (95% range), weeks 40.3 (36.7, 42.3) 
Birth weight, mean (SD), g 3453.9 (498.5) 
Birth length, mean (SD), cm 50.3 (2.3) 
Birth head circumference, mean (SD), cm 33.8 (1.7) 
Preterm birth, No. (%) 35 (2.5) 
Small size for gestational age, No. (%) 114 (8.3) 
Values are observed data and represent means (SD), medians (95% range), or 
number of subjects (valid %). 
SD, standard deviation. 
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circumference and length (Table 2, basic models in eTable S2). The as-
sociations of maternal pregnancy-averaged phthalic acid, LMWP, 
HMWP or DEHP concentrations with fetal weight differed based on 
timing of outcome measurement (p-values for interaction < 0.05). 
An IQR increase in pregnancy-averaged phthalic acid (Fig. 1A), 
LMWP (Fig. 1B), HMWP (Fig. 1C) or DEHP (Fig. 1D) concentrations 
tended to be associated with lower fetal weight SDS across gestation. 
The associations of phthalic acid and LMWP with fetal weight became 
stronger as pregnancy progressed, so that we observed no significant 
associations at 20 and 30 weeks but significant associations at 40 weeks 
(differences − 0.08 (95% CI − 0.14 to − 0.02) SDS and − 0.09 (95% CI 
− 0.16 to − 0.02) SDS per interquartile range increase in phthalic acid 
and LMWP, respectively), although these associations were no longer 
significant after multiple testing correction. Similarly, the associations 
of trimester-specific phthalic acid (Fig. 2A), LMWP (Fig. 2B), HMWP 
(Fig. 2C) or DEHP (Fig. 2D) concentrations with fetal weight in the 
second and third trimester and at birth showed a tendency for lower 
weight SDS at birth as a result of exposure to these phthalate metabo-
lites. We observed differences by timing of exposure in these associa-
tions. An IQR increase in maternal phthalic acid and LMWP 
concentrations measured in the second trimester, but not in the first or 
third trimester, was associated with lower weight at birth (differences 
− 0.09 (95% CI − 0.15 to − 0.01) SDS and − 0.08 (95% CI − 0.15 to 
− 0.02) SDS, respectively). However, these associations did not remain 
statistically significant after multiple testing correction. The results of 
the trimester-specific models for head circumference and length are 
shown in eTable S3. Higher maternal first and second trimester LMWP 
concentrations were associated with smaller head circumference SDS in 
the third trimester and at birth, respectively (p-values < 0.05). Also, 
higher maternal second trimester DNOP concentrations were associated 
with higher length SDS in the second and third trimester (p-values <
0.05). None of these associations survived multiple testing correction. 
Similar associations were observed in mutually adjusted models 
(eTable S4). When assessing the associations of the individual phthalate 
metabolites with fetal growth measurements, monoethylphthalate 
seems to be the metabolite that mainly drives the association of higher 
maternal LMWP concentrations with smaller head circumference SDS in 
the third trimester and at birth (eTable S5). Higher maternal second and 
third trimester mono-isobutylphthalate and mono-n-butylphthalate 
concentrations (LMWP metabolites) were associated with lower length 
SDS at birth (p-values < 0.05). Higher maternal mono-isobutylphthalate 
concentrations in all trimesters were also associated with lower weight 
SDS at birth (p-values < 0.05). After correction for multiple testing, an 
IQR increase in maternal mono-2-heptylphthalate concentrations in the 
first trimester was associated with 0.11 (95% CI 0.18 to 0.05) SDS lower 
weight at birth and an IQR increase in mono-[(2-carboxymethyl)hexyl] 
phthalate concentrations in the second trimester was associated with 
0.11 (95% CI 0.19 to 0.04) SDS lower length at birth. 
3.3. Maternal phthalate metabolites concentrations and birth outcomes 
Maternal pregnancy-averaged and trimester-specific phthalate me-
tabolites concentrations were not associated with the risks of preterm 
birth or small size for gestational age at birth (Table 3, unadjusted 
models in eTable S6 and mutually adjusted models in eTable S7). When 
assessing the individual phthalate metabolites, higher maternal first 
trimester mono-n-butylphthalate and mono-2-heptylphthalate concen-
trations and pregnancy-averaged mono-(2-ethyl-5-oxohexyl)phthalate 
concentrations were associated with an increased risk of preterm birth 
(eTable S8). Higher first trimester mono-2-heptylphthalate, pregnancy- 
averaged and second and third trimester monobenzylphthalate, and 
third trimester mono-n-butylphthalate and mono-(2-ethyl-5-carbox-
ypentyl)phthalate concentrations were associated with an increased risk 
of being born small for gestational age. All these associations for the 
individual phthalate metabolites were no longer significant after 
correction for multiple testing. In the sensitivity analyses addressing 
gestational age at birth continuously, higher first trimester phthalic acid, 
mono-2-heptylphthalate and mono-(2-ethyl-5-carboxypentyl)phthalate 
concentrations were associated with lower gestational age at birth while 
higher third trimester mono-n-butylphthalate and mono-(2-ethyl-5- 
hydroxyhexyl)phthalate concentrations were associated with higher 
gestational age at birth. These associations did not remain significant 
after multiple testing correction (eTable S9). 
4. Discussion 
In this population-based prospective cohort study, we observed that 
higher maternal phthalic acid, LMWP, HMWP and DEHP concentrations 
tended to be associated with lower fetal weight across gestation. Higher 
concentrations of specific LMWP, HMWP and DEHP metabolites were 
also associated with smaller head circumference and lower length at 
birth and an increased risk of preterm birth and small size for gestational 
age at birth. We observed differences by timing of exposure in these 
associations. 
4.1. Interpretation of main findings 
Fetal growth restriction and preterm birth are linked to adverse 
health outcomes throughout life (Sun et al., 2018; Raju et al., 2017). 
Fetal exposure to phthalates may adversely affect placental formation 
and subsequently early growth and development (Yang et al., 2019). 
Previous studies on the associations of repeatedly assessed maternal 
Table 2 
Maternal pregnancy-averaged phthalate metabolites concentrations and fetal growth measures.   
Head circumference Length Weight 
Effect estimate, SDS 
(95% Confidence 
Interval) 
p-value for interaction 
with gestational age 
Effect estimate, in SDS 
(95% Confidence 
Interval) 
p-value for interaction 
with gestational age 
Effect estimate, SDS 
(95% Confidence 
Interval) 
p-value for interaction 
with gestational age 
Phthalic 
acid 
0.10 (− 0.06, 0.26) 0.14 0.13 (− 0.02, 0.28) 0.10 0.17 (0.05, 0.30)† 0.001†
LMWP 0.09 (− 0.08, 0.26) 0.05 0.07 (− 0.09, 0.23) 0.37 0.18 (0.05, 0.31)* 0.002†
HMWP − 0.04 (− 0.18, 0.10) 0.48 0.02 (− 0.11, 0.15) 0.87 0.11 (0.00, 0.22)* 0.04* 
DEHP − 0.05 (− 0.19, 0.09) 0.40 0.01 (− 0.12, 0.14) 0.95 0.11 (0.00, 0.22)* 0.05* 
DNOP 0.04 (− 0.10, 0.18) 0.68 0.08 (− 0.05, 0.22) 0.26 0.09(− 0.02, 0.20) 0.17 
Main effects and p-values for interaction with gestational age at growth measurement obtained from linear mixed effects models. Main effects reflect the difference in 
fetal growth measures in SDS for an interquartile range increase in each natural log-transformed pregnancy-averaged phthalate metabolite in µmol/g creatinine. 
Models include fetal sex, maternal age, pre-pregnancy body mass index, educational level, ethnicity, parity, smoking habits, alcohol consumption, daily caloric intake, 
folic acid supplement use, and gestational age at growth measurement. Models include an interaction term between exposure concentration and gestational age at 
growth measurement, a random intercept for each participant, and a random slope for gestational age at growth measurement. *p-value < 0.05; †p-value < 0.007. 
DEHP, di-2-ethylhexylphthalate; DNOP, di-n-octylphthalate; HMWP, high molecular weight phthalate; LMWP, low molecular weight phthalate; SDS, standard de-
viation scores. 
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phthalate metabolites during pregnancy with weight, length and head 
circumference at birth showed inconsistent results (Kamai et al., 2019). 
In a study among 482 US pregnant women, higher pregnancy-averaged 
concentrations of metabolites of HMWP, particularly DEHP metabolites, 
were associated with lower fetal growth (Ferguson et al., 2016). In a 
French study among mother-son pairs, there was a trend towards a lower 
estimated fetal weight with increasing fetal HMWP exposure (Botton 
et al., 2016). However, in a study among 390 mother-child pairs from 
the INMA-Sabadell cohort, average pregnancy exposure to sum of DEHP 
or LMWP was not significantly associated with fetal growth or birth 
outcomes (Casas et al., 2016). In the present study, higher maternal 
phthalic acid, LMWP, HMWP and DEHP concentrations tended to be 
associated with lower fetal weight across gestation. Higher concentra-
tions of specific LMWP, HMWP and DEHP metabolites were also asso-
ciated with smaller head circumference and lower length at birth and an 
increased risk of small size for gestational age at birth. On the other 
hand, we observed a positive association between maternal second 
trimester DNOP concentrations and fetal femur length in second and 
Fig. 1. Maternal pregnancy-averaged phthalate metabolites concentrations and fetal weight. Plots illustrate the associations between maternal pregnancy-averaged 
phthalic acid (A), LMW phthalate (B), HMW phthalate (C) and DEHP (D) concentrations with fetal weight by gestational age at growth measurement obtained from 
linear mixed effects models. Effect estimates at 20, 30 or 40 weeks reflect the difference (95% confidence interval) in fetal weight in SDS at these specific time points 
for an interquartile range increase in each natural log-transformed pregnancy-averaged phthalate metabolite in µmol/g creatinine. Models include fetal sex, maternal 
age, pre-pregnancy body mass index, educational level, ethnicity, parity, smoking habits, alcohol consumption, daily caloric intake, folic acid supplement use, and 
gestational age at growth measurement. Models include an interaction term between exposure concentration and gestational age at growth measurement, a random 
intercept for each participant, and a random slope for gestational age at growth measurement. *p-value < 0.05. CI, confidence interval; DEHP, di-2- 
ethylhexylphthalate; HMW phthalate, high molecular weight phthalate; IQR, interquartile range; LMW phthalate, low molecular weight phthalate; SDS, standard 
deviation scores. 
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third trimester. Although we cannot disregard this finding, we did not 
observe consistency across trimesters of exposure and time points of 
outcome assessment. Altogether, these findings suggest that fetal 
exposure to specific phthalates during pregnancy seems to be related 
with fetal growth restriction. 
Maternal exposure to phthalates might influence gestational length. 
Fig. 2. Maternal trimester-specific phthalate metabolites concentrations and fetal weight. Plots illustrate the associations between maternal trimester-specific 
phthalic acid (A), LMWP (B), HMWP (C) and DEHP (D) concentrations with fetal weight in the second and third trimester and at birth obtained from linear 
regression models. Values are regression coefficients (95% confidence intervals) that reflect the differences in fetal weight in SDS in the second and third trimester 
and at birth for an interquartile range increase in each natural log-transformed trimester-specific phthalate metabolites in µmol/g creatinine. Models include fetal sex 
(except for weight at birth), maternal age, pre-pregnancy body mass index, educational level, ethnicity, parity, smoking habits and alcohol consumption during each 
trimester, daily caloric intake and folic acid supplement use. *p-value < 0.05. DEHP, di-2-ethylhexylphthalate; HMWP, high molecular weight phthalate; LMWP, low 
molecular weight phthalate; PA, phthalic acid; SDS, standard deviation scores. 
Table 3 
Maternal pregnancy-averaged and trimester-specific phthalate metabolites concentrations and preterm birth and small size for gestational age at birth.   
Preterm birth Odds Ratio (95% Confidence Interval) Small size for gestational age at birth Odds Ratio (95% Confidence Interval) 
Pregnancy- 
averaged 
First trimester Second 
Trimester 
Third trimester Pregnancy- 
averaged 





0.90 (0.58, 1.42) 1.14 (0.78, 
1.66) 
0.97(0.60, 1.56) 0.92 (0.60, 
1.43) 
























1.16 (0.94, 1.42) 1.04 (0.83, 
1.31) 
1.17(0.94, 1.45) 1.24 (0.98, 
1.55) 
























Values are odds ratios (95% confidence intervals) from binary logistic regression models that reflect the risk of preterm birth and small size for gestational age at birth 
for an interquartile range increase in each natural log-transformed pregnancy-averaged and trimester-specific phthalate metabolites in µmol/g creatinine. Models 
include maternal age, pre-pregnancy body mass index, ethnicity, educational level, parity, folic acid supplement use, alcohol consumption and smoking habits during 
pregnancy or during each trimester and daily caloric intake. 
DEHP, di-2-ethylhexylphthalate; DNOP, di-n-octylphthalate; HMWP, high molecular weight phthalate; LMWP, low molecular weight phthalate. 
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Studies, mainly from the USA, reported associations of maternal 
phthalate metabolites concentrations with an increased odds of preterm 
birth (Ferguson et al.,2014, 2019; Chin et al., 2019; Gao et al., 2019; 
Boss et al., 2018), although there are also multiple studies that reported 
no associations. (Kalloo et al., 2020; Bloom et al., 2019; Zhang et al., 
2020) In our study, maternal trimester-specific and pregnancy-averaged 
grouped phthalate concentrations were not associated with the risk of 
preterm birth. However, there were some associations of individual 
phthalates with an increased risk of preterm birth and with a shorter 
gestational age at birth. 
We observed differences in associations according to trimester of 
exposure, suggesting that first and second trimester might be particu-
larly sensitive windows to exposure. Early to mid-pregnancy is a time of 
rapid placental and fetal development, which might be mediating the 
observed associations. Phthalate exposure has been found to imbalance 
fatty acids (Xu et al., 2005), change placental thyroid hormone receptor 
signaling in rodent trophoblast cells (Yu et al., 2018), and cause 
oxidative stress mediating DNA damage in human trophoblast cells 
(Tetz et al., 2013), which can lead to fetal growth restriction and pre-
term birth (Yang et al., 2017, 2018; Ferguson et al., 2015). Also, 
phthalate exposure was associated with changes in both the DNA 
methylome and transcriptome of human placentas (Grindler et al., 
2018). 
The findings may be difficult to interpret clinically because the effect 
estimates are small. However, even small differences in fetal growth and 
gestational length may be crucial for health in later life. Since most as-
sociations were no longer significant after multiple testing correction, 
we cannot exclude the possibility of some results being chance findings. 
Further studies are needed to replicate these findings and investigate 
causality and potential mechanisms. 
4.2. Methodological considerations 
The major strengths of this study were the large sample size, the 
population-based cohort design from early life onwards, the availability 
of three urine measurements of phthalate metabolites concentrations, 
and the use of repeated fetal growth measures during pregnancy and at 
birth. Women in this subgroup did not substantially differ from the 
broader cohort and thus, although it cannot be excluded, selection bias 
seems unlikely (Philips et al., 2018a). The level of toxicity for phthalate 
exposure on fetal growth development is uncertain. Urinary concen-
trations of phthalate metabolites found in our study population were 
generally somewhat lower as those reported by other studies of pregnant 
women performed in the same time period (Philips et al., 2018a). 
Phthalates have short biological half-lives (Braun et al., 2013), although 
it has been suggested that a single urine sample reasonably reflects 
exposure for up to 3 months (Hauser et al., 2004). Variability seems to 
be compound specific, with reasonable correlations for DEHP metabo-
lites and stronger correlations for LMWP metabolites and mono-
benzylphthalate (Braun et al., 2012). In our study, we observed 
moderate variability for phthalates across pregnancy. Thus, measure-
ment error may have led to an underestimation of the trimester-specific 
effect estimates. The effect estimates for the pregnancy-averaged asso-
ciations may be less affected by measurement error, but may lack 
interpretability if trimester-specific effects are present. A linear pattern 
was observed for the associations between maternal pregnancy- 
averaged phthalic acid, LMWP, HMWP and DEHP concentrations with 
fetal weight by gestational age at growth measurement. We have growth 
measurements available at two time points during pregnancy and at 
birth. This limited number of measurements might have precluded the 
detection of non-linear growth variation. We found limited confounding 
of effect estimates when adjusting for the confounding factors. Effect 
estimates of the basic or unadjusted models as compared to the adjusted 
models were largely similar and in the same direction. Although we 
adjusted for a large number of potential confounders, residual con-
founding due to unmeasured lifestyle, sociodemographic and clinical 
characteristics might still be present in the observed associations. 
4.3. Conclusion 
Fetal exposure to phthalate metabolites seems to be related with fetal 
growth restriction and preterm birth. Phthalates may have trimester 
specific effects on fetal growth and birth outcomes. 
Disclosure statement 
The authors have nothing to disclose. 
Funding 
The general design of the Generation R Study is made possible by 
financial support from the Erasmus MC, University Medical Center, 
Rotterdam, the Netherlands, the Organization for Health Research and 
Development (ZonMw) and the Ministry of Health, Welfare and Sport. 
This study was supported by grants RO1ES-022972 and RO1ES-029779 
from the National Institutes of Health, USA. The content is solely the 
responsibility of the authors and does not represent the official views of 
the National Institutes of Health. This work was supported by the Eu-
ropean Union’s Horizon 2020 research and innovation programme 
under grant agreement 874,583 (ATHLETE Project). VWVJ received 
additional grant from the European Research Council (ERC Consolidator 
Grant, ERC-2014-CoG-64916). 
CRediT authorship contribution statement 
Susana Santos: Methodology, Formal analysis, Writing - original 
draft. Chalana M. Sol: Methodology, Formal analysis, Writing - original 
draft. Charissa van Zwol – Janssens: Methodology, Formal analysis, 
Writing - original draft. Elise M. Philips: Methodology, Writing - review 
& editing. Alexandros G. Asimakopoulos: Investigation, Writing - re-
view & editing. Maria-Pilar Martinez-Moral: Investigation, Writing - 
review & editing. Kurunthachalam Kannan: Investigation, Writing - 
review & editing. Vincent W.V. Jaddoe: Conceptualization, Resources, 
Supervision, Funding acquisition, Writing - review & editing. Leonardo 
Trasande: Conceptualization, Resources, Supervision, Funding acqui-
sition, Writing - review & editing. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Acknowledgments 
We gratefully acknowledge the contribution of the participating 
children, their mothers, general practitioners, hospitals, midwives, and 
pharmacies in Rotterdam. 
Appendix A. Supplementary material 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.envint.2021.106443. 
References 
Bloom, M.S., Wenzel, A.G., Brock, J.W., et al., 2019. Racial disparity in maternal 
phthalates exposure; Association with racial disparity in fetal growth and birth 
outcomes. Environ. Int. 127, 473–486. 
Boss, J., Zhai, J., Aung, M.T., et al., 2018. Associations between mixtures of urinary 
phthalate metabolites with gestational age at delivery: a time to event analysis using 
summative phthalate risk scores. Environ Health. 17 (1), 56. 
S. Santos et al.                                                                                                                                                                                                                                  
Environment International 151 (2021) 106443
8
Botton, J., Philippat, C., Calafat, A.M., et al., 2016. Phthalate pregnancy exposure and 
male offspring growth from the intra-uterine period to five years of age. Environ. 
Res. 151, 601–609. 
Braun, J.M., Smith, K.W., Williams, P.L., et al., 2012. Variability of urinary phthalate 
metabolite and bisphenol A concentrations before and during pregnancy. Environ. 
Health Perspect. 120 (5), 739–745. 
Braun, J.M., Sathyanarayana, S., Hauser, R., 2013. Phthalate exposure and children’s 
health. Curr. Opin. Pediatr. 25 (2), 247–254. 
Casas, M., Valvi, D., Ballesteros-Gomez, A., et al., 2016. Exposure to bisphenol A and 
phthalates during pregnancy and ultrasound measures of fetal growth in the INMA- 
Sabadell cohort. Environ. Health Perspect. 124 (4), 521–528. 
Casas, M., Basagana, X., Sakhi, A.K., et al., 2018. Variability of urinary concentrations of 
non-persistent chemicals in pregnant women and school-aged children. Environ. Int. 
121 (Pt 1), 561–573. 
Chin, H.B., Jukic, A.M., Wilcox, A.J., et al., 2019. Association of urinary concentrations 
of early pregnancy phthalate metabolites and bisphenol A with length of gestation. 
Environ Health. 18 (1), 80. 
Crider, K.S., Yang, T.P., Berry, R.J., Bailey, L.B., 2012. Folate and DNA methylation: a 
review of molecular mechanisms and the evidence for folate’s role. Adv Nutr. 3 (1), 
21–38. 
Ferguson, K.K., McElrath, T.F., Ko, Y.A., Mukherjee, B., Meeker, J.D., 2014. Variability in 
urinary phthalate metabolite levels across pregnancy and sensitive windows of 
exposure for the risk of preterm birth. Environ. Int. 70, 118–124. 
Ferguson, K.K., McElrath, T.F., Chen, Y.H., Mukherjee, B., Meeker, J.D., 2015. Urinary 
phthalate metabolites and biomarkers of oxidative stress in pregnant women: a 
repeated measures analysis. Environ. Health Perspect. 123 (3), 210–216. 
Ferguson, K.K., Meeker, J.D., Cantonwine, D.E., Chen, Y.H., Mukherjee, B., McElrath, T. 
F., 2016. Urinary phthalate metabolite and bisphenol A associations with ultrasound 
and delivery indices of fetal growth. Environ. Int. 94, 531–537. 
Ferguson, K.K., Rosen, E.M., Barrett, E.S., et al., 2019. Joint impact of phthalate exposure 
and stressful life events in pregnancy on preterm birth. Environ. Int. 133 (Pt B), 
105254. 
Gao, H., Wang, Y.F., Huang, K., et al., 2019. Prenatal phthalate exposure in relation to 
gestational age and preterm birth in a prospective cohort study. Environ. Res. 176, 
108530. 
Grindler, N.M., Vanderlinden, L., Karthikraj, R., et al., 2018. Exposure to phthalate, an 
endocrine disrupting chemical, alters the first trimester placental methylome and 
transcriptome in women. Sci. Rep. 8 (1), 6086. 
Hadlock, F.P., Harrist, R.B., Sharman, R.S., Deter, R.L., Park, S.K., 1985. Estimation of 
fetal weight with the use of head, body, and femur measurements–a prospective 
study. Am. J. Obstet. Gynecol. 151 (3), 333–337. 
Hauser, R., Calafat, A.M., 2005. Phthalates and human health. Occup. Environ. Med. 62 
(11), 806–818. 
Hauser, R., Meeker, J.D., Park, S., Silva, M.J., Calafat, A.M., 2004. Temporal variability 
of urinary phthalate metabolite levels in men of reproductive age. Environ. Health 
Perspect. 112 (17), 1734–1740. 
Hornung, R.W.R.L., 1990. Estimation of average concentration in the presence of 
nondetectable values. Appl. Occup. Environ. Hyg. 5 (1), 46–51. 
Kalloo, G., Wellenius, G.A., McCandless, L., et al., 2020. Exposures to chemical mixtures 
during pregnancy and neonatal outcomes: The HOME study. Environ. Int. 134, 
105219. 
Kamai, E.M., McElrath, T.F., Ferguson, K.K., 2019. Fetal growth in environmental 
epidemiology: mechanisms, limitations, and a review of associations with 
biomarkers of non-persistent chemical exposures during pregnancy. Environ. Health. 
18 (1), 43. 
Klipstein-Grobusch, K., den Breeijen, J.H., Goldbohm, R.A., et al., 1998. Dietary 
assessment in the elderly: validation of a semiquantitative food frequency 
questionnaire. Eur. J. Clin. Nutr. 52 (8), 588–596. 
Kooijman, M.N., Kruithof, C.J., van Duijn, C.M., et al., 2016. The generation R study: 
design and cohort update 2017. Eur. J. Epidemiol. 31 (12), 1243–1264. 
Li, M.X., Yeung, J.M., Cherny, S.S., Sham, P.C., 2012. Evaluating the effective numbers of 
independent tests and significant p-value thresholds in commercial genotyping 
arrays and public imputation reference datasets. Hum. Genet. 131 (5), 747–756. 
Mose, T., Mortensen, G.K., Hedegaard, M., Knudsen, L.E., 2007. Phthalate monoesters in 
perfusate from a dual placenta perfusion system, the placenta tissue and umbilical 
cord blood. Reprod. Toxicol. 23 (1), 83–91. 
Niklasson, A., Ericson, A., Fryer, J.G., Karlberg, J., Lawrence, C., Karlberg, P., 1991. An 
update of the Swedish reference standards for weight, length and head 
circumference at birth for given gestational age (1977–1981). Acta Paediatr Scand. 
90 (8–9), 756–762. 
Noor, N., Ferguson, K.K., Meeker, J.D., et al., 2019. Pregnancy phthalate metabolite 
concentrations and infant birth weight by gradations of maternal glucose tolerance. 
Int. J. Hyg. Environ. Health 222 (3), 395–401. 
Philips, E.M., Jaddoe, V.W.V., Asimakopoulos, A.G., et al., 2018a. Bisphenol and 
phthalate concentrations and its determinants among pregnant women in a 
population-based cohort in the Netherlands, 2004–5. Environ. Res. 161, 562–572. 
Philips, E.M., Kahn, L.G., Jaddoe, V.W.V., et al., 2018b. First trimester urinary bisphenol 
and phthalate concentrations and time to pregnancy: a population-based cohort 
analysis. J. Clin. Endocrinol. Metab. 103 (9), 3540–3547. 
Philips, E.M., Trasande, L., Kahn, L.G., Gaillard, R., Steegers, E.A.P., Jaddoe, V.W.V., 
2019. Early pregnancy bisphenol and phthalate metabolite levels, maternal 
hemodynamics and gestational hypertensive disorders. Hum. Reprod. 34 (2), 
365–373. 
Philips, E.M., Santos, S., Steegers, E.A.P., et al., 2020a. Maternal bisphenol and phthalate 
urine concentrations and weight gain during pregnancy. Environ. Int. 135, 105342. 
Philips, E.M., Jaddoe, V.W.V., Deierlein, A., et al., 2020b. Exposures to phthalates and 
bisphenols in pregnancy and postpartum weight gain in a population-based 
longitudinal birth cohort. Environ. Int. 144, 106002. 
Raju, T.N.K., Buist, A.S., Blaisdell, C.J., Moxey-Mims, M., Saigal, S., 2017. Adults born 
preterm: a review of general health and system-specific outcomes. Acta Paediatr. 106 
(9), 1409–1437. 
Royal College of Obstetricians and Gynaecologists, 2000. Routine ultrasound screening 
in pregnancy: protocol. RGOG Press, London.  
Santos, S., Zugna, D., Pizzi, C., Richiardi, L., 2019. Sources of confounding in life course 
epidemiology. J. Dev. Orig. Health Dis. 10 (3), 299–305. 
Sol, C.M., Santos, S., Asimakopoulos, A.G., et al., 2020. Associations of maternal 
phthalate and bisphenol urine concentrations during pregnancy with childhood 
blood pressure in a population-based prospective cohort study. Environ. Int. 138, 
105677. 
Sood, S., Shekhar, S., Santosh, W., 2017. Dimorphic placental stress: A repercussion of 
interaction between endocrine disrupting chemicals (EDCs) and fetal sex. Med. 
Hypotheses 99, 73–75. 
Sun, D., Wang, T., Heianza, Y., et al., 2018. Birthweight and cardiometabolic risk 
patterns in multiracial children. Int. J. Obes. (Lond). 42 (1), 20–27. 
Tetz, L.M., Cheng, A.A., Korte, C.S., et al., 2013. Mono-2-ethylhexyl phthalate induces 
oxidative stress responses in human placental cells in vitro. Toxicol. Appl. 
Pharmacol. 268 (1), 47–54. 
Tielemans, M.J., Steegers, E.A., Voortman, T., et al., 2016. Protein intake during 
pregnancy and offspring body composition at 6 years: the Generation R Study. Eur. J. 
Nutr. 
van den Dries, M.A., Guxens, M., Spaan, S., et al., 2020. Phthalate and bisphenol 
exposure during pregnancy and offspring nonverbal IQ. Environ. Health Perspect. 
128 (7), 77009. 
van Zwol-Janssens, C., Trasande, L., Asimakopoulos, A.G., et al., 2020. Fetal exposure to 
bisphenols and phthalates and childhood bone mass: a population-based prospective 
cohort study. Environ. Res. 186, 109602. 
Verburg, B.O., Steegers, E.A., De Ridder, M., et al., 2008. New charts for ultrasound 
dating of pregnancy and assessment of fetal growth: longitudinal data from a 
population-based cohort study. Ultrasound Obstet. Gynecol. 31 (4), 388–396. 
Xu, Y., Cook, T.J., Knipp, G.T., 2005. Effects of di-(2-ethylhexyl)-phthalate (DEHP) and 
its metabolites on fatty acid homeostasis regulating proteins in rat placental HRP-1 
trophoblast cells. Toxicol. Sci. 84 (2), 287–300. 
Yang, C., Lim, W., Bazer, F.W., Song, G., 2017. Oleic acid stimulation of motility of 
human extravillous trophoblast cells is mediated by stearoyl-CoA desaturase-1 
activity. Mol. Hum. Reprod. 23 (11), 755–770. 
Yang, C., Lim, W., Bazer, F.W., Song, G., 2018. Down-regulation of stearoyl-CoA 
desaturase-1 increases susceptibility to palmitic-acid-induced lipotoxicity in human 
trophoblast cells. J. Nutr. Biochem. 54, 35–47. 
Yang, C., Song, G., Lim, W., 2019. A mechanism for the effect of endocrine disrupting 
chemicals on placentation. Chemosphere 231, 326–336. 
Yu, Z., Han, Y., Shen, R., et al., 2018. Gestational di-(2-ethylhexyl) phthalate exposure 
causes fetal intrauterine growth restriction through disturbing placental thyroid 
hormone receptor signaling. Toxicol. Lett. 294, 1–10. 
Zhang, Y., Mustieles, V., Yland, J., et al., 2020. Association of parental preconception 
exposure to phthalates and phthalate substitutes with preterm birth. JAMA Netw. 
Open. 3 (4), e202159. 
S. Santos et al.                                                                                                                                                                                                                                  
